Biosecure Lawmakers Target China Studies in New Regulatory Push

New Focus on China Studies::
Biosecure lawmakers are now focusing on clinical trials conducted in China, particularly those run by multinational drugmakers at sites affiliated with Chinese entities.

BIOSECURE Act Implications::
The proposed BIOSECURE Act aims to block federal funding for U.S.-based companies that do business with select Chinese service companies or CDMOs, potentially impacting both Chinese contractors and U.S.-based biotech firms.

Market Impact::
The U.S. biotech sector has seen significant growth, while the Chinese biotech market has declined, partly due to investor concerns over the BIOSECURE Act.

Industry Reactions::
The bill has received bipartisan support but mixed reactions from experts, with some arguing it could enhance national security and others warning it might limit access to top research partners and competition.

Supply Chain Shifts::
Many U.S. life sciences firms are already planning to shift their supply sourcing away from China due to the proposed legislation.